Tag: Angus Xie
Multinational antitrust reviews in pharma M&A
In recent years, M&A in the global biopharmaceutical sector has remained highly active
Han Kun, Zhong Lun act on Sino Biopharm’s USD950m LaNova buy
Han Kun and Zhong Lun advised on Sino Biopharm’s USD950m acquisition of cancer drugmaker LaNova Medicines
The A-List 2023-24: Rising Stars
When helping clients navigate a complex legal landscape, young elite lawyers have brought fresh ideas and innovative approaches to the table














